Studies
Current Clinical Trials
Clinical Study (Sanofi EFC16461 - Dupilumab for Chronic Idiopathic Urticaria)
The company Sanofi is currently recruiting chronic idiopathic urticaria patients for a clinical study of its new drug Dupixent in multiple sites in Canada and the US. Dupixent is already approved for use in asthma, eczema and nasal polyps.
If you are interested in participating, you should discuss this option with your doctor. More information on study sites and admissibility criteria is available at csutrial.com.
Aziz
Ghafoor
Aziz Abdul Ghafoor is a second-year medical student at UBC with a passion for dermatology and patient advocacy. Originally from Afghanistan and raised in Canada, Aziz Is dedicated to improving health outcomes for marginalized communities.
His work with Chronic Urticaria Canadian Chronic Urticaria Society) reflects his commitment to supporting patients who face chronic skin conditions. Through this partnership, he aims to raise awareness, foster support networks, and provide educational resources to empower individuals affected by chronic urticaria across Canada.